Lexaria Bioscience warrants exercised at reduced price of USD 12.92 per share

The incentive package includes unregistered Series A warrants for 453,969 shares, exercisable immediately at $12.67 and expiring five years after the resale statement becomes effective.

It also includes short-term unregistered Series B warrants for 453,969 shares, exercisable immediately at $12.67 and expiring 18 months after the resale statement becomes effective.

Lexaria entered agreements for immediate cash exercise of warrants covering 453,969 common shares at a reduced $12.92 per share.

Gross proceeds are expected at about $5.9 million, before fees, with closing expected on or about Sept. 9, 2026.

The company plans to file a resale registration statement covering shares issuable on exercise of the new warrants.